Literature DB >> 25864953

Hippocampal, amygdala and nucleus accumbens volume in first-episode schizophrenia patients and individuals at high familial risk: A cross-sectional comparison.

Catherine Bois1, Liat Levita2, Isabelle Ripp3, David C G Owens4, Eve C Johnstone4, Heather C Whalley4, Stephen M Lawrie4.   

Abstract

It is unknown whether brain changes occur prior to onset of schizophrenia or after it develops. Prospective familial high risk studies provide a good method to investigate this. In the Edinburgh High Risk Study, structural MRI scans of 150 young individuals at familial high risk of schizophrenia, 34 patients with first-episode schizophrenia and 36 matched controls were obtained. Of the high risk participants with scans suitable for analysis, 17 developed schizophrenia after the scans were taken, whilst 57 experienced isolated or sub-clinical psychotic symptoms, and 70 remained well. We used Freesurfer to extract volumetric measurements of the hippocampus, amygdala and nucleus accumbens with the aim of assessing whether any alterations found were present in all those at high risk, or selectively in the high risk cohort based on future clinical outcome, or only in those experiencing their first-episode of psychosis. We found no significant differences in any examined regions between controls and those at high risk, or between those at high risk who later developed schizophrenia and those who remained well. However, patients with first-episode schizophrenia demonstrated significant volumetric reductions in the bilateral hippocampus, left amygdala, and right nucleus accumbens compared to high risk individuals and healthy controls, which were not significantly associated with the intake of anti-psychotic medication or duration of illness. We found that patients had significantly smaller left amygdalae and bilateral hippocampus compared to HR[ill]. Our findings suggest that volumetric reductions of the hippocampus, amygdala and nucleus accumbens occur early in the first-episode of psychosis. The apparent absence of high risk versus control differences we found using Freesurfer is at odds with our previous studies conducted on the same sample, and possible methodological reasons for these apparent discrepancies are discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amygdala; High-risk; Hippocampus; Nucleus accumbens; Schizophrenia; Structural MRI

Mesh:

Year:  2015        PMID: 25864953     DOI: 10.1016/j.schres.2015.03.024

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

1.  Development of a computerized adaptive screening tool for overall psychopathology ("p").

Authors:  Tyler M Moore; Monica E Calkins; Theodore D Satterthwaite; David R Roalf; Adon F G Rosen; Ruben C Gur; Raquel E Gur
Journal:  J Psychiatr Res       Date:  2019-06-01       Impact factor: 4.791

2.  Structural Brain Abnormalities in Youth With Psychosis Spectrum Symptoms.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Monica E Calkins; Simon N Vandekar; Guray Erus; Kosha Ruparel; David R Roalf; Kristin A Linn; Mark A Elliott; Tyler M Moore; Hakon Hakonarson; Russell T Shinohara; Christos Davatzikos; Ruben C Gur; Raquel E Gur
Journal:  JAMA Psychiatry       Date:  2016-05-01       Impact factor: 21.596

3.  Is neuroimaging clinically useful in subjects at high risk for psychosis?

Authors:  Stefan Borgwardt; André Schmidt
Journal:  World Psychiatry       Date:  2016-06       Impact factor: 49.548

4.  Subcortical Brain Volume Abnormalities in Individuals With an At-risk Mental State.

Authors:  Daiki Sasabayashi; Yoichiro Takayanagi; Tsutomu Takahashi; Naoyuki Katagiri; Atsushi Sakuma; Chika Obara; Masahiro Katsura; Naohiro Okada; Shinsuke Koike; Hidenori Yamasue; Mihoko Nakamura; Atsushi Furuichi; Mikio Kido; Yumiko Nishikawa; Kyo Noguchi; Kazunori Matsumoto; Masafumi Mizuno; Kiyoto Kasai; Michio Suzuki
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

5.  Choroid Plexus Enlargement and Allostatic Load in Schizophrenia.

Authors:  Yan-Fang Zhou; Jun-Chao Huang; Ping Zhang; Feng-Mei Fan; Song Chen; Hong-Zhen Fan; Yi-Min Cui; Xing-Guang Luo; Shu-Ping Tan; Zhi-Ren Wang; Wei Feng; Ying Yuan; Fu-De Yang; Anya Savransky; Meghann Ryan; Eric Goldwaser; Joshua Chiappelli; Laura M Rowland; Peter Kochunov; Yun-Long Tan; L Elliot Hong
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

6.  Schizophrenia-like reduced sensorimotor gating in intact inbred and outbred rats is associated with decreased medial prefrontal cortex activity and volume.

Authors:  Carles Tapias-Espinosa; Cristóbal Río-Álamos; Ana Sánchez-González; Ignasi Oliveras; Daniel Sampedro-Viana; Maria Del Mar Castillo-Ruiz; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel
Journal:  Neuropsychopharmacology       Date:  2019-04-16       Impact factor: 7.853

7.  Chronic mild stress impairs latent inhibition and induces region-specific neural activation in CHL1-deficient mice, a mouse model of schizophrenia.

Authors:  Mona Buhusi; Daniel Obray; Bret Guercio; Mitchell J Bartlett; Catalin V Buhusi
Journal:  Behav Brain Res       Date:  2017-06-21       Impact factor: 3.332

8.  Volumetric data of normal nucleus accumbens from magnetic resonance imaging scans.

Authors:  Theodosios Birbilis; Achilleas Siozopoulos; Aliki Fiska; Savas Deftereos; Eleni Kaldoudi; Vassilios Karagiannis; Vassilios Thomaidis
Journal:  Med Pharm Rep       Date:  2021-10-30

Review 9.  Sex differences in the developing brain: insights from multimodal neuroimaging.

Authors:  Antonia N Kaczkurkin; Armin Raznahan; Theodore D Satterthwaite
Journal:  Neuropsychopharmacology       Date:  2018-06-06       Impact factor: 7.853

10.  More Consistently Altered Connectivity Patterns for Cerebellum and Medial Temporal Lobes than for Amygdala and Striatum in Schizophrenia.

Authors:  Henning Peters; Junming Shao; Martin Scherr; Dirk Schwerthöffer; Claus Zimmer; Hans Förstl; Josef Bäuml; Afra Wohlschläger; Valentin Riedl; Kathrin Koch; Christian Sorg
Journal:  Front Hum Neurosci       Date:  2016-02-17       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.